NEW YORK (GenomeWeb) — Cofactor Genomics announced today that its ImmunoPrism Immune Profiling kit will be used in a Phase I/IIa clinical study of Genocea Biosciences' personalized cancer vaccine candidate GEN-009.

Launched in October, the RNA-based kit allows for the preparation, sequencing, and immune composition analysis of solid tumors against Cofactor's database of machine learning-optimized immune reference expression models.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.